Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombiVIT: ritlecitinib plus narrowband UVB versus ritlecitinib alone for non-segmental vitiligo
2025-521504-22-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of ritlecitinib tosilate in Vitiligo (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Percent change from baseline in F-VASI at Week 52. Planned start Oct 2025; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-521504-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521504-22-00.